PATH

What PATH does

PATH is a 501(c)(3) nonprofit global health organization founded in 1977 and headquartered in Seattle, Washington, that develops, deploys, and scales health innovations for underserved populations in 70+ countries. The organization operates through a portfolio model spanning product development, health system strengthening, and direct program implementation. Core technical assets include the Center for Vaccine Innovation and Access (CVIA)—responsible for vaccine development and access programs including MenAfriVac (delivered to 360M+ people across Africa's meningitis belt), PNEUMOSIL pneumococcal conjugate vaccine, and typhoid conjugate vaccine introduction in six countries protecting 56M+ children—alongside the Community Health Information Platform (CHIP), a digital system for community health workers with DHIS2 and SmartCare interoperability. Diagnostics work centers on the WHO-prequalified STANDARD G6PD Test (developed with SD Biosensor) and AI-enabled clinical tools. The organization also operates Ultra Rice, a fortified rice product in partnership with Abbott reaching nearly 500,000 children in Karnataka, India.

PATH's business model is grant-funded: it does not sell products commercially. Revenue derives from project-specific foundation grants (Gates Foundation, Rockefeller Foundation), government contracts (national health ministries in Malawi, Zambia, and others), and multilateral funding (Unitaid, UNICEF, CEPI). Recent 2025–2026 inflows include $11M from Unitaid for the MADE diagnostics manufacturing program, $6.4M from Pfizer Foundation for West Africa infectious disease programs, and a Bristol Myers Squibb Foundation grant for India hemoglobinopathies work. Programs are delivered through partnerships with national health systems, NGOs, and implementing organizations, with PATH providing technical assistance, capacity building, and program management. The organization employs 1,700+ people across 23 country offices and reports reaching 150M+ people annually with health interventions. Subsidiary PATH Vaccine Solutions (PVS) functions as a tax-exempt supporting entity funding CVIA projects.

Name

PATH

Legal name

PATH

Website

https://path.org

Company type

Private

Founded year

1977

Operating status

Operating

Headcount range

1–10 employees

Short description

PATH is a 501(c)(3) nonprofit global health organization founded in 1977 that develops and scales vaccines, diagnostics, digital health platforms, and nutritional products for underserved populations across 70+ countries, funded primarily by foundation grants and government contracts.

Ownership category

akta.pro rank

Product category

Global Health Services

NAICS

Voluntary Health Organizations (813212)

SIC

Services-Health Services (8000), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Global Health Research, Clinical Trials & Product Development Partnerships (PDPs) (HLAJAOAM)

akta.pro secondary industries

Disease-Specific Global Programs (HIV/TB/Malaria/NTDs) (HLAJAKAF), Health Promotion, Prevention & Community Health Programs (BPAIAJAC)

Keywords

• Global health programs
• Vaccine development access
• Diagnostic tools manufacturing
• Digital health platforms
• Health systems strengthening

Headquarters

HQ city

Seattle

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Foundation Grants and Donations: Primary revenue stream from major foundation partners including Bill & Melinda Gates Foundation, Rockefeller Foundation, and other philanthropic organizations that provide grant funding for health programs and research
2. Government Grants and Contracts: Funding from government agencies and multilateral organizations including Unitaid, CEPI, UNICEF, and national health ministries for specific health programs and initiatives
3. Program Implementation Services: Technical assistance and program implementation services provided to governments and implementing partners in exchange for contracted funding

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

PATH is a global health nonprofit that develops, deploys, and scales up health innovations to improve health for people in low- and middle-income countries. It delivers a portfolio spanning vaccine development and access (Center for Vaccine Innovation and Access), diagnostic products (e.g., STANDARD G6PD Test), digital health solutions (Community Health Information Platform), fortified nutrition products (Ultra Rice), and AI-powered clinical decision support tools. Programs are funded primarily through grants and implemented in partnership with governments, multilaterals, foundations, and NGOs across 70+ countries.

Product overview

PATH is a global health nonprofit organization that develops and delivers health technologies and programs rather than a single unified product. The organization's core offerings span vaccine development and access (through its Center for Vaccine Innovation and Access), diagnostic tools (including the STANDARD G6PD Test), digital health solutions (such as the Community Health Information Platform for community health workers), nutritional products (Ultra Rice fortified rice), and AI-powered health tools. PATH works across 70+ countries to advance health equity through innovation and partnerships, providing technical assistance, program implementation, and health technologies targeting diseases including malaria, pneumonia, typhoid, and meningitis.

Differentiator

Problem solved

Functional benefit

Brands

• PATH Vaccine Solutions (PVS): An affiliate of PATH that funds projects conducted by PATH's Center for Vaccine Innovation and Access. It is a nonprofit corporation with 501(c)(3) tax-exempt status and a supporting organization of PATH.
• Center for Vaccine Innovation and Access (CVIA)
• Center for Advocacy and Policy
• Digital Square
• Center for Vaccine Introduction and Access (CVIA)
• Digital and Data Transformation
• PATH Malaria

Products and services

• Center for Vaccine Innovation and Access (CVIA) PATH's center that accelerates the development and delivery of lifesaving vaccines for communities facing the greatest health risks, managing a portfolio of vaccines in development and deployment against pneumonia, diarrhea, malaria, and other diseases.
• Community Health Information Platform (CHIP) A digital health system that equips community health workers with tools to register families, record vaccinations, and track health visits in real time, with interoperability designed for DHIS2 and SmartCare integration.
• STANDARD G6PD Test A diagnostic test developed by SD Biosensor and PATH to measure glucose-6-phosphate dehydrogenase (G6PD) deficiency, used to identify patients eligible for tafenoquine treatment of P. vivax malaria.
• Ultra Rice A fortified rice product developed in partnership with Abbott to combat malnutrition by adding essential vitamins, minerals, and iron while maintaining the taste and appearance of traditional rice; currently feeding nearly 500,000 children in Karnataka through school feeding programs.
• MenAfriVac The world's first conjugate meningitis A vaccine, delivered to over 360 million people across the African meningitis belt, developed through partnership and virtually eliminating meningitis A wherever used.
• PNEUMOSIL An affordable pneumococcal conjugate vaccine developed to increase protection for children against deadly pneumonia and other pneumococcal diseases like meningitis, sepsis, and otitis media.
• Typhoid Conjugate Vaccines Typhoid conjugate vaccine introduction programs supporting more than 56 million children across six initial countries, with ongoing campaigns in countries such as Kenya and Malawi.
• Malaria Vaccines Support Program Technical assistance and implementation support for malaria vaccine rollout, including support for RTS,S/AS01 vaccine introduction in Ghana, Kenya, Malawi, and subsequent rollout in 16+ countries including Uganda, Nigeria, and DRC.
• AI Health Tools AI-powered clinical decision support tools including AI Consult for clinical error detection at Penda Health clinics in Kenya (16% reduction in diagnostic errors), Ada Health's symptom assessment integrated into South Africa's MomConnect maternal health platform, and AI-enabled portable digital x-ray machines for TB screening in Kenya.
• Digital Health Programs Digital and data transformation initiatives including the Zambia Digital Community Health Project, disease surveillance systems, and AI-enabled diagnostic tools for malaria, TB, and other infectious diseases.
• P. vivax Malaria Treatment Tools (Tafenoquine and STANDARD G6PD Test) WHO-prequalified P. vivax malaria treatment tools including single-dose tafenoquine (co-developed with GSK) and the STANDARD G6PD Test (developed by SD Biosensor and PATH), delivered through the PAVE partnership with Medicines for Malaria Venture, Unitaid, and the Bill & Melinda Gates Foundation.
• MADE Program - African Diagnostics Manufacturing PATH-led program supporting African companies in developing and scaling diagnostic test production for regional and global markets, funded by an $11 million Unitaid grant as part of a nearly $50 million investment in African diagnostics and essential medicines manufacturing.
• Ultra Rice Manufacturing Expansion (Lower-Cost Extrusion Process) Expanded Ultra Rice manufacturing capacity using a lower-cost extrusion process, supported by a $1.5 million Abbott Fund grant, that reduced production costs by 10 percent and supports school feeding programs reaching nearly 500,000 children in Karnataka, India.

Quantifiable outcome

• 150 million+ people reached annually with health interventions
• +1 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability9 records

Feature4 records

Partnerships

Seven partnerships are on record, tiered core, flagship and minor.

• AbbottcoreStrategic or Co-development PartnerPartnership for Ultra Rice fortified rice product development and distribution to address micronutrient deficiencies globally
• CEPI (Coalition for Epidemic Preparedness Innovations)flagshipStrategic or Co-development PartnerCollaboration on the 100 Days Mission for rapid vaccine development against epidemic threats
• UNICEFcoreStrategic or Co-development PartnerPartnership on Zambia digital health project and other child health initiatives
• Government of Malawi Ministry of HealthcoreStrategic or Co-development PartnerSHIELD project implementation for health systems strengthening and disease prevention in Malawi
• Reach Digital HealthminorStrategic or Co-development PartnerCollaboration on MomConnect AI study to evaluate artificial intelligence applications in maternal health
• Medicines for Malaria Venture (MMV)coreStrategic or Co-development PartnerPAVE partnership for advancing malaria treatments and prevention tools
• GSKcoreStrategic or Co-development PartnerVarious collaborations on vaccine development and global health access initiatives

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Clinton Health Access Initiative (CHAI): CHAI is a global health nonprofit operating in 35+ countries with a similar model of partnering with governments and funders to expand access to medicines, vaccines, and diagnostics in LMICs. Its roughly comparable size, funder base, and product development partnership model make it the closest direct peer to PATH.
• Gavi, the Vaccine Alliance: Gavi funds vaccine introduction and scale-up in low-income countries. PATH is a key implementation partner to Gavi on vaccine introductions (typhoid, malaria, HPV), and both share the same funder ecosystem (Gates Foundation, UNICEF, WHO) and focus on accelerating vaccine access.
• Jhpiego: A Johns Hopkins University affiliate nonprofit that partners with country health systems to deliver maternal, newborn, and child health, family planning, and infectious disease services in LMICs. Jhpiego's programmatic model of technical assistance and capacity building directly mirrors PATH's health systems strengthening work.
• Management Sciences for Health (MSH): MSH is a global health nonprofit focused on health systems strengthening, pharmaceutical management, and supply chain in LMICs, with a similar funding profile (USAID, foundations) and country-level implementation footprint as PATH. Both compete for similar grants supporting ministry-of-health capacity building.
• FHI 360: FHI 360 is a large human development nonprofit with significant global health programming in infectious disease, maternal/child health, and health systems across dozens of LMICs. Its mix of research, programmatic implementation, and contract-funded model overlaps closely with PATH's.
• Medicines for Malaria Venture (MMV): MMV is a product development partnership co-leading the PAVE program with PATH on P. vivax malaria tools. Both share a PPP structure focused on developing and delivering malaria interventions in LMICs with overlapping funder support.

Broad incumbents

• UNICEF: UNICEF is a much larger UN agency with a global health mandate that includes vaccine procurement and delivery, nutrition, and maternal/child health. PATH works as an implementing partner to UNICEF on Zambia digital health and other initiatives, but UNICEF operates at a vastly larger scale with country presence in 190+ countries.
• World Health Organization (WHO): WHO sets global health norms, prequalifies vaccines and diagnostics (a key dependency for PATH's product introductions), and convenes country health responses. WHO is not a competitor for implementation funding but is a critical counterpart whose standards and priorities shape PATH's program pipeline.
• Save the Children: Save the Children operates large-scale health, nutrition, and education programs across 100+ countries with substantial global health programming. While broader in mission than PATH, it competes for similar donor funding and implements comparable maternal/child health and infectious disease interventions.

Others

• Bill & Melinda Gates Foundation: The Gates Foundation is PATH's largest single funder and also funds direct country investments, alternative intermediaries, and global health R&D outside PATH. While not a peer in the operational sense, it is the most consequential ecosystem player whose strategy directly determines PATH's funding runway.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/PATHtweets
• YouTubeyoutube.com/user/globalhealthcatalyst
• Facebookfacebook.com/PATHglobalhealth
• LinkedInlinkedin.com/company/path
• Instagraminstagram.com/pathglobalhealth

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Subsidiaries1 record

Funding overview

Funding rounds6 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PATH